Background: Pseudomonas aeruginosa can become resistant to carbapenems by both intrinsic (mutationdriven) and transferable (b-lactamase-based) mechanisms. Knowledge of the prevalence of these various mechanisms is important in intensive care units (ICUs) in order to define optimal prevention and therapeutic strategies.
Introduction
Development of carbapenem resistance is common in Pseudomonas aeruginosa, especially in intensive care units (ICUs), where the selective pressure exerted by antibiotics on bacterial populations is strong. 1 This well-known situation is mostly due to the occurrence of mutations or insertion sequences (ISs) inactivating the gene that codes for porin OprD, the specific portal of entry for carbapenems into this organism (for a recent review see Lister et al. 2 ). The reduced outer membrane permeability that results from OprD loss usually causes a 4-fold to 16-fold increase in the MICs of all the carbapenem molecules, including imipenem, meropenem and doripenem, in strains with inducible or constitutive ampC expression. 3 In addition to this very prevalent mechanism, P. aeruginosa may collect foreign genes encoding Ambler class A (e.g. GES and KPC types), class B (e.g. AIM, GIM, IMP, NDM, SPM and VIM types) or class D (e.g. OXA-198) b-lactamases able to hydrolyse carbapenems to varying degrees. 4 -7 Over the last decade an ever-growing number of P. aeruginosa isolates producing metallo-b-lactamase (MBL) (class B) have been reported from many countries, suggesting that these enzymes could become the predominant cause of carbapenem resistance in the near future. However, the resistance patterns to individual carbapenems may vary greatly among clinical strains as a result of complex interplay between enzymatic and non-enzymatic mechanisms, some of which still await characterization. 2 For instance, MICs of meropenem and doripenem may be influenced by the overproduction of MexAB-OprM, a multidrug efflux system able to extrude all these molecules except imipenem. 8 -12 Little is known about the genetic events leading to downregulation of oprD expression and carbapenem resistance in clinical P. aeruginosa isolates. The transcription of this gene, driven by the distinct promoters P1 and P2, is subject to complex regulation. 2 Indeed, although the expression of oprD is stimulated when bacteria are grown in the presence of some substrates (e.g. arginine), it is repressed in some in vitro mutants overproducing the active efflux system MexEF-OprN, MexXY/OprM or CzcCBA. 2 These multispecific pumps, which belong to the resistance-nodulation -cell division family of transporters, can export various antibiotic substrates including fluoroquinolones (MexEFOprN, MexXY/OprM), aminoglycosides, tetracyclines, macrolides, b-lactams (MexXY/OprM) and heavy metals such as zinc, cadmium and cobalt (CzcCBA). 13 -15 It is now established that the inverse regulation of OprD and MexEF-OprN depends on MexT. 16, 17 This LysR-type transcriptional regulator behaves both as an activator of operon mexEF-oprN and a repressor of oprD in nfxC mutants carrying mutations in mexS, a gene encoding a probable quinone oxidoreductase. 18 MexT divergent regulatory effects on mexEF-oprN and oprD were also observed in a laboratory mutant from which the gene for master regulator AmpR had been deleted, though this was not coupled with an increased resistance to carbapenems. 19 Recent data from our laboratory demonstrate that mutations in the two-component regulatory system ParRS may result in down-regulation of oprD expression as well, while increasing that of mexXY and of lipopolysaccharide modification operon arnBCADTEF-ugd. 20 Such multidrug-resistant mutants have been named agrW2. Finally, Perron et al. 15 reported that mutations in another signal transduction system, CzcRS, which positively controls the expression of operon czcCBA, were associated with low transcription levels of oprD and increased carbapenem MICs. However, the functional link coupling the OprD uptake pathway to efflux systems remains unclear because these diffusion/transport processes do not seem to have substrates in common. In contrast to OprDdeficient isolates exhibiting mutations or IS in the oprD promoters, 2 regulatory mutants with affected OprD production as a result of increased efflux have not clearly been identified in the clinical setting.
This study was initially designed to establish the prevalence of carbapenem-hydrolysing b-lactamases in imipenem-nonsusceptible ICU strains of P. aeruginosa, as epidemiological data are lacking regarding this important issue. Our attention was subsequently drawn by a subpopulation of bacteria exhibiting full-length OprD porins (as deduced from oprD genes showing an open reading frame of expected length) and overproducing the efflux pumps MexEF-OprN, MexXY/OprM and CzcCBA, respectively. Here, we show that such regulatory mutants can be isolated from severely ill patients and deserve more attention regarding their pathogenicity and the conditions of their emergence.
Materials and methods

Bacterial strains
All the non-duplicate ICU isolates of P. aeruginosa showing nonsusceptibility to imipenem (MIC .4 mg/L; EUCAST breakpoints) were prospectively collected by the laboratories of 26 French public hospitals (GESPAR Group) during the month of June 2010. Members of the GESPAR Group (Groupe d'Etude de la Sensibilité de Pseudomonas Aeruginosa en Réanimation) are listed in the Acknowledgements section. The strains (n¼109) were mostly isolated from respiratory specimens (60%), catheters (9%), urine (9%) and blood cultures (5.5%). PAO1 was used as the wild-type reference strain in drug susceptibility tests and as a comparator in reverse transcription real-time quantitative PCR (RT-qPCR) experiments. All the strains were routinely cultured either in Mueller-Hinton broth (MHB; Bio-Rad, Marnes-la-Coquette, France) or on Mueller-Hinton agar plates at 358C, supplemented with appropriate antibiotics where necessary.
Susceptibility testing
MICs of indicated antibiotics were determined in two independent experiments by the microbroth dilution method with microplates containing specifically designed drug panels (Sensititre; Thermo Fisher Scientific). The microplates were inoculated with 10 5 cfu/mL in calcium-adjusted MHB (Becton Dickinson, Le Pont de Claix, France) and incubated at 358C for 18 h as recommended. 21 Strains were considered as susceptible, intermediate or resistant to individual antimicrobials according to the current EUCAST breakpoints indicated in Table 2 (http://www.eucast.org).
Detection of carbapenemase-producing isolates
The whole bacterial collection was screened for MBL production by a double-disc synergy test using EDTA as an inhibitor of enzymatic activity. 22 An enlargement (≥3 mm) of the inhibition zone around an imipenem disc (10 mg, Bio-Rad) and/or a ceftazidime disc (30 mg, Bio-Rad) in the direction of a disc loaded with 10 mL EDTA 0.5 mM, pH 8.0 was considered as a positive result. In parallel, the 109 strains were assayed spectrophotometrically (Uvikon, Serlabo w ) for imipenem hydrolysis with cell sonicates prepared from 20-fold concentrated log-phase cultures in MHB supplemented with 50 mg/L of cefoxitin, a strong inducer of the expression of intrinsic cephalosporinase AmpC and thus of potential extendedspectrum AmpC (ESAC) enzymes. 23 Degradation of imipenem at 100 mM final concentration in 66 mM sodium phosphate (pH 7.0) was recorded at 299 nm according to standard procedures. 24 Strains producing enzymes VIM-1 and VIM-2 were used as positive controls.
Gene amplification and sequencing
The carbapenemase-encoding genes were amplified by PCR and sequenced in all ceftazidime-resistant strains, including those exhibiting imipenem-hydrolysing activity spectrophotometrically. The specific primers used to amplify the genes coding for GES-, KPC-, IMP-, VIM-, GIM-, SPM-, NDM-type b-lactamases are presented in Table 1 . The presence of genes coding for PER-, VEB-, TEM-, SHV-, BEL-and OXA-type extendedspectrum b-lactamases (ESBLs) was also investigated in the ceftazidimenon-susceptible isolates, as previously reported. 25 The PCR amplicons were sequenced on both strands by using the BigDye Terminator kit (PE Applied Biosystems) in an ABI Prism 3100 DNA sequencer (PE Applied Biosystems). The resulting sequences were compared with those deposited at GenBank (http://www.ncbi.nih.gov/BLAST). In all the clinical isolates the porin oprD gene, along with its promoter region (starting 2107 nt relative to the start codon), was amplified by PCR and sequenced by using specific primers ( Table 1 ). The resulting sequences were compared with those of reference strains PAO1, PA14, LESB58 and PP2, a clinical LESB58 derivative ≥8-fold more susceptible to meropenem than imipenem. 26 
RT-qPCR experiments
Specific gene expression was measured by RT-qPCR as described previously. 27 Briefly, 2 mg of total RNA were treated with ImpromII reverse
Complexity of imipenem resistance in ICU P. aeruginosa 1773 JAC transcriptase as specified by the manufacturer (Promega). The resulting cDNA fragments were quantified in a Rotor Gene RG6000 real-time PCR instrument (Qiagen) by using fluorescent dye SybrGreen (Fast SybrGreen kit, Qiagen) and primers, as already reported for genes oprD, mexE, mexB, 27 mexY, PA1797, 20 czcR, czcC and copR. 28 The mRNA levels were normalized in each strain to that of housekeeping gene rpsL and expressed as ratios to the values of strain PAO1 (by definition set at 1). The RT-qPCR data presented here are means of at least two independent experiments. Well-characterized mutants overexpressing mexEF-oprN (PAO7H), mexAB-oprM (PT629), mexXY (CMZ091) and PA1797 (PAOW2) were used as positive controls in order to assess the involvement in resistance of efflux mechanisms MexEF-OprN, MexAB-OprM and MexXY/OprM, respectively. 20, 27, 29 Reference strain PAO1 pre-treated with sublethal concentrations of ZnCl 2 (300 mM) served as a positive control to assess the overexpression of genes czcR and czcC as reported by Caille et al.
28
Immunodetection of OprD
Bacterial membranes were isolated, subjected to SDS-PAGE and analysed by western blotting with OprD-specific polyclonal antiserum (diluted 1 :10 000), as reported previously. 30 
Genotyping experiments
Clondiag w chips (P. aeruginosa genotyping kit, Alere), which allow the identification of 14 single-nucleotide polymorphisms (SNPs) in the core genome, were used to genotypically compare the 109 selected isolates. As previously described, the combination of SNPs allows the assignment of a genetic fingerprint (referred to by a hexadecimal code) to each strain. 31 
Genotyping by multilocus sequence typing (MLST)
Determination of the sequence types (ST) of the most represented clones was performed according to the protocol of van Mansfeld et al. 32 by using the P. aeruginosa MLST web site (http://pubmlst.org/paeruginosa/).
Results
Features of the selected ICU strains
One hundred and nine imipenem-non-susceptible P. aeruginosa isolates were prospectively collected from ICU patients in 26 French hospitals over a 1 month period (June 2010). Analysis of these strains with Clondiag w chips discriminated 48 SNP patterns with 27, 9, 7, 1, 1, 1, 1 and 1 patterns being represented by 1, 2, 3, 4, 6, 7, 9 and 17 isolates, respectively. In most cases the clonally related isolates were recovered from the same hospital or from hospitals located in a same region. The most represented clones OC2E (n¼ 6), E469 (n¼ 7), 2C1A (n¼ 9) and F469 (n¼ 17) were found to belong to ST395, ST298, ST175 and ST235, respectively. ST175 (serotype O:4) and ST235 (serotype O:11) are widespread international clones. 33, 34 In agreement with this, F469 was traced in 12 hospitals (see Table S1 for complete data, available as Supplementary data at JAC Online). As indicated in Table 2 , all the strains were intermediate or resistant to imipenem, but 22.9% and 11.9% remained susceptible to meropenem and doripenem, respectively, according to the current EUCAST breakpoints. The latter two agents showed similar MIC distributions. Of the 109 isolates 7.3% were susceptible to all the b-lactams tested except carbapenems, and 59.6% were susceptible to ceftazidime. PCR experiments performed on the ceftazidime-resistant population (n¼ 44) demonstrated the presence of genes coding for MBL in seven strains and for ESBLs (PER-1, n¼ 1; GES-9, n¼ 1; VEB-1a, n¼ 1; OXA-19, n¼ 1) in four other strains. Genes bla VIM-2 and bla GES-1 coexisted in a single isolate, NANC10. Susceptibility rates to ciprofloxacin and amikacin were 34.9% and 78%, respectively. Finally, among the three strains resistant to colistin (MIC ¼ 8 mg/L), only one (CRE05) fitted with the definition of pandrug resistance. 35 
Prevalence of carbapenemases
As indicated above, seven isolates (6.4%) from five hospitals were found to harbour genes encoding a class B MBL, namely VIM-1 (n¼ 1), VIM-2 (n¼ 4), VIM-4 (n¼ 1) or IMP-29 (n¼ 1). Genotypic analysis of the VIM-2-producing strains showed that three from the same hospital were clonally related. Interestingly, all of the seven MBL-producing strains could be detected phenotypically by the imipenem-EDTA (n¼7) and/or ceftazidime-EDTA (n¼6) double-disc synergy test. ESBL GES-1 masked the ceftazidime-EDTA synergy in strain NANC10. Despite extensive PCR screening, none of the ICU strains appeared to harbour genes coding for class A carbapenemases. Similarly, no evidence of imipenem-hydrolysing AmpC variants (ESAC) was obtained by using UV spectrophotometry and concentrated cell sonicates (data not shown). By contrast, all the MBL-producing strains were strongly positive with this assay.
MBL-producing strains exhibited high levels of resistance to ticarcillin (MIC ≥512 mg/L) and ceftazidime (≥64 mg/L). While five of the seven isolates were highly resistant to the three carbapenems tested (MIC ≥128 mg/L), two displayed susceptibility levels to imipenem similar to those of some carbapenemasenegative strains (MIC¼ 32 mg/L) (Figure 1) . One of these isolates (BES01) produced IMP-29, an enzyme related to IMP-8 with greater activity towards meropenem and doripenem (MIC¼ 64 mg/L) than imipenem. 36 The other strain (NANC10) was found by RT-qPCR to express the bla VIM-2 gene 5-fold less than the other isolates positive for VIM-2.
Mutants with disrupted oprD genes
Qualitative or quantitative alterations of porin OprD are well-known causes of resistance to carbapenems in clinical P. aeruginosa isolates. 2 To gain insight into the contribution of this specific uptake pathway to the resistance of the ICU isolates, we amplified and sequenced the oprD genes in the carbapenemase-positive (n¼7) and carbapenemase-negative (n¼102) bacteria. Despite repeated attempts and the use of various pairs of primers, the genes from five strains (including one positive for VIM-4) could not be amplified, strongly suggesting either large deletions or insertions in the genomic region carrying oprD (data not shown). Gene sequence analysis of the 104 remaining strains allowed their classification into three groups. A first group of 89 (85.6%) isolates, including three MBL producers, was found to contain single point mutations, nucleotide insertions or deletions generating frameshifts or premature stop codons in the oprD gene, leading to its inactivation. In 9 of these 89 isolates the gene was disrupted by an IS. Some of the elements identified, such as ISPa1635 (n¼1) and ISPa1328 (n¼3 clonally related strains from distantly located hospitals), have already been reported to cause imipenem resistance. 37 Other IS initially characterized in Shigella dysenteriae (IS911, n¼1), Pseudomonas stutzeri (ISPs1, n¼1), Pseudomonas savastanoi (IS51, n¼1) as well as P. aeruginosa (IS222, n¼1; ISPa41, n¼1) also inactivated oprD in the ICU isolates. Only a few strains exhibited identical mutations or IS, even within predominant clones, indicating that imipenem resistance emerged mainly independently in the different hospitals.
Mutants with wild-type or variant OprD porins
In a second group of seven strains (6.7%), including one MBL-positive P. aeruginosa (NANC10), the predicted amino acid sequence of OprD was identical to that of functional porins from reference strains PAO1 (n¼1), PA14 (n¼ 1) and LESB58 (n¼ 5). The third group of eight isolates (7.7%) exhibited amino acid variations (up to three) in OprD compared with wild-type reference strains. BES04, ETI02 and TOUL04 produced chimeric (mosaic) proteins combining sequences from PAO1 and PA14. In a recent paper, Ocampo-Sosa et al. 38 demonstrated that such mosaic porins are functional and may be found in carbapenem-susceptible strains (porin types defined as T1-II and T1-IIa). More importantly, three amino acids (L 11 , A 12 and V 13 ) were missing in the signal sequence of OprD in TOUL04. Complexity of imipenem resistance in ICU P. aeruginosa GAR05 differed from LESB58 by the mutation K 268 Q in porin loop L6, while the clonally related VIM-4-positive strains PBI06 and PBI10 contained the variation K 399 N in transmembrane stretch TMS 15, according to the crystal structure established by Biswas et al. 39 CLI03 differed from strain PP2 by the mutation H 288 D located in TMS 13. Finally, GAR02 produced a chimeric OprD deriving from LESB58 and PP2 with an additional A 267 P mutation in L6.
Porin oprD expression
RT-qPCR experiments demonstrated decreased expression of oprD, from 3-fold to 100-fold, in all the strains from groups 2 and 3 as compared with PAO1 (Table 3 ). In nine strains (BES04, ETI02, GAR01, GAR02, GAR04, GAR05, PAP01, VAL02, VES03) the poor oprD expression correlated with absent or very low amounts of porin in the outer membrane (immunoblots shown in Figure 2 ). Interestingly, in the other six strains (CLI03, NANC05, NANC10, PBI06, PBI10, TOUL04) no or very faint OprD bands could be detected on immunoblots despite some degree of gene expression (from 0.1 to 0.3 times that of PAO1). In TOUL04, alteration of the signal sequence is predicted to prevent the porin from translocating across the cytoplasmic membrane. As mentioned earlier, strains CLI03, PBI06 and PBI10 produced single amino acid variants from PP2 and LESB58, respectively (Table S2 , available as Supplementary data at JAC Online). The corresponding substitutions (H288D, K399N) were localized by the PyMOL software outside the pore in the b-sheets of the porin barrel presumed to interact with the peptidoglycan or outer membrane lipids. Whether such mutations impair the transport to or the insertion of OprD into the outer membrane needs to be confirmed. Finally, as NANC05 and NANC10 produce wild-type LESB58 OprD, we performed additional western blotting experiments with wholemembrane extracts. The protein was detected in these extracts but not in the outer membrane subfraction, thereby suggesting a deficient transport across the inner membrane (data not shown).
Mechanisms associated with oprD down-regulation
Various mutational events may be responsible for stable downregulation of oprD expression. Indeed, imipenem resistance has been associated with mutations that: (i) inactivate at least one of the oprD promoters; 40 (ii) activate regulatory proteins involved in resistance to heavy metals; 15, 28 or (iii) are implied in the regulation of multidrug efflux pumps MexEF-OprN and MexXY 16, 18, 20 in in vitro-selected mutants. Sequencing of the genomic region upstream of oprD in the 15 clinical strains of groups 2 and 3 revealed the presence of ISPsy2, No (2), faint (+), low (+) and wild-type (++) amounts of OprD on immunoblots. c Relative to expression in PAO1 (value of 1 by definition). Values are geometric means of at least two independent determinations. Isolates were considered as MexEF-OprN, MexAB-OprM or MexXY/OprM hyperproducers when the expression levels of mexE, mexB or mexY were ≥100-fold, ≥2-fold and ≥4-fold higher than those of PAO1, respectively. 60 The significant values are indicated in bold. d In ETI02 the promoter region of oprD is disrupted by ISPsy2. e GAR01 was genotypically related to GAR05, and PBI06 to PBI10.
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a 1194 bp element (described for the first time in Pseudomonas syringae) 41 that disrupts the putative -35 sequence of the P2 promoter in ETI02. The promoter regions of the other 14 strains were identical to that of PAO1. To analyse these bacteria further we quantified the transcripts of copR and czcR, which code for transcriptional regulators CopR and CzcR, respectively. When activated by their respective cognate sensor kinases (CopS and CzcS), these regulators turn on the expression of efflux operon czcCBA and repress oprD transcription. 15, 28 One strain, BES04, was found to strongly overexpress czcR (Table 3) . Consistent with this, sequencing of the czcR-czcS operon revealed a T283A mutation in the predicted histidine kinase domain of CzcS, with respect to PAO1 and PA14 CzcS. 15 These results support the notion of CzcRS being constitutively activated in BES04. Surprisingly, RT-qPCR experiments showed only a modest 2-fold increase in czcC expression in that strain compared with PAO1. Of note, exposure of PAO1 to 300 mM of zinc as an inducing metal enhanced czcR and czcC transcripts by 42-fold and 995-fold, respectively. In agreement with our transcription data, BES04 was no more resistant to zinc than PAO1 (MICs of 10 mM and 15 mM, respectively). These results were clarified when an IS (ISPre2) initially described in Pseudomonas resinovorans was discovered in BES04; 42 ISPre2 interrupts the promoter sequences of operon czcCBA, likely preventing its induction.
The expression of mexE from the mexEF-oprN operon was also measured by RT-qPCR. In nfxC mutants the activation of LysRtype regulator MexT results in overproduction of the efflux pump MexEF-OprN and repression of oprD expression. This can be achieved through mutations occurring in mexS, which resides near mexT and codes for a putative oxidoreductase, MexS. 18, 43 Three of the 15 strains (GAR02, PAP01, VAL02) were shown to be mutants overproducing MexEF-OprN. In each of them we identified amino acid substitutions in MexS (V73A and P98L in GAR02; F10S and V73A in PAP01; A75V and D272N in VAL02) with respect to the PA14 and PAO1 sequences (MexT was identical to that of PA14). One of these mutations, A75V, which is close to V73A, has already been identified in clinical nfxC strains. 43 It should be noted that none of our nfxC isolates harboured an inactive gene ampR; all the AmpR regulators showed the same sequence as that of PAO1 and PA14.
Like MexEF-OprN, the efflux pump MexXY/OprM is unable to export imipenem.
14 However, our laboratory recently reported that mutations activating the two-component system ParRS up-regulate operon mexXY and turn down oprD expression. 20 Such mutants, named agrW2, overexpress PA1797, a gene adjacent to the parRS operon. In 9 of 15 selected strains, RT-qPCR experiments demonstrated concomitant overexpression of PA1797 (≥11.4-fold more than in PAO1) and mexY (≥4.3-fold) ( Table 3) . Sequencing of parS and parR in these bacteria confirmed the presence of amino acid substitutions in the sensor ParS and/or the response regulator ParR that potentially activate the phosphorelay (Table 3 ). In four strains (GAR01, GAR05, NANC10, VES03) the mutations were located near the phosphorylation site D57, including the already reported change M59I. 20 Other mutations were situated in the first (L11I in GAR04) or the second (A138D in NANC10; L145M in PBI06 and PBI10) transmembrane domain of ParS, considered as being important for signal transduction. In NANC05 the mutation L54Q affected the periplasmic domain of the sensor.
Discussion
This study is the first to specifically evaluate the prevalence of carbapenemases in imipenem-non-susceptible French ICU strains of P. aeruginosa. Although the rates of MBL P. aeruginosa are lower in France than reported for other countries, 44 -49 they are now high enough to recommend hospital laboratories to routinely screen for MBLs. We believe that strains resistant to both imipenem and ceftazidime should be prioritized for phenotypic testing for MBL detection as 16% (7 of 44) were shown to produce such enzymes. All the MBL-and/or ESBL-positive strains from this study belonged to the subset of strains (n¼ 23/109) resistant to both ceftazidime and tobramycin, which may help to optimize the application of additional detection tests.
With the notable exception of IMP-29, found in a single hospital, 36 the carbapenem-hydrolysing b-lactamases identified in the present work (VIM-1, VIM-2 and VIM-4) tend to become increasingly prevalent in many Gram-negative species worldwide. 4 Interestingly, all the collected strains were deficient in porin OprD, including the seven carbapenemase-positive isolates. Analysis of the whole bacterial collection revealed that a variety of mechanisms can alter this carbapenem-specific uptake pathway. As expected, mutational inactivation of the oprD gene represents the major cause of OprD loss in ICU P. aeruginosa strains. 2 However, this study also highlights a significant number of insertional events involving different IS, some of which (IS911, ISPs1, IS222, IS51, ISPa41 and ISPa1328) have never been associated with imipenem resistance before or have never to our knowledge even been reported in P. aeruginosa (IS911, ISPs1, and IS51). Collectively these data confirm the role played by these mobile elements in the emergence of carbapenem resistance in this species (9 of 104 isolates; 8.7%). 23, 50, 51 As many as 94 of the 109 strains (86.2%), including 90 carbapenemase-negative strains, were found to harbour inactivated oprD genes and could be considered 'classical' impermeabilitytype mutants. However, our attention was attracted by 15 isolates (including three VIM-2 producers) expressing a wild-type (i.e. identical to reference strain PAO1, PA14, LESB58 or PP2) or Complexity of imipenem resistance in ICU P. aeruginosa mosaic full-length porin OprD. As OprD is known to have high sequence polymorphism among environmental and clinical strains of P. aeruginosa, 52, 53 we wondered whether these sequence variations might have an impact on the diffusion of some or all of the carbapenem molecules and thus be linked with particular resistance phenotypes. While this cannot be excluded, RT-qPCR, western blotting and DNA sequencing experiments clearly demonstrated that production of OprD was deficient in all these isolates, mainly as a result of inverse coregulation of oprD with active efflux systems CzcCBA (n¼ 1), MexXY (n¼ 9) and MexEF-OprN (n¼3). Overexpression of czcR, mexY (and PA1797) and mexE in the corresponding strains was associated with mutations in CzcR, in the two-component system ParRS and in oxidoreductase MexS, respectively. As reported by Perron et al., 15 OprD-defective mutants harbouring a V194L substitution in the CzcS sensor protein can be selected in vitro on lethal concentrations of zinc. The present study is the first to establish a link between the emergence of mutations in CzcS and resistance of P. aeruginosa to carbapenems in the clinical setting. In strain BES04 this was not accompanied by a higher zinc MIC because of the disruption the promoter sequence of operon czcCBA by ISPre2. Accordingly, heavy metals (zinc, cadmium and cobalt) do not seem to have played a role in the selection of the BES04 mutation.
This work confirms that agrW2 mutants are clinically relevant and not just laboratory-selected organisms. 20 Such mutants seem to be relatively prevalent in the imipenem-resistant population (9 of 15 isolates investigated; ≥8.3% of the whole collection). These bacteria, which typically overexpress the efflux pump components MexXY along with PA1797 (a protein of unknown function coded by a gene adjacent to operon parRS), exhibit decreased susceptibility to aminoglycosides, fluoroquinolones and imipenem. Four of the nine clinical agrW2 mutants were also slightly (2-fold) more resistant than wild-type strains to colistin, as reported previously for in vitro-selected isolates. 20 Although in vitro-selected mutants that overproduce MexEF-OprN have been reported to exhibit increased resistance to carbapenems, 54 ,55 a recent study from our laboratory showed that 7 of 10 clinical nfxC strains remained susceptible to imipenem, two isolates being of intermediate susceptibility and one isolate being resistant to this antibiotic (EUCAST breakpoints ≤4 and .8 mg/L, respectively). 43 Thus, the three nfxC mutants detected in the present work (MIC 8 mg/L) should not be taken as representative of those prevailing among ICU strains (MIC ≤4 mg/L).
Finally, in the remaining strains, the lack of OprD in the outer membrane was associated with disruption of the oprD promoter P2 by ISPsy2 (ETI02) and alteration of the porin signal sequence (TOUL04). Several other amino acid substitutions in OprD were noted in strains devoid of porin at the cell surface. Additional experiments are required to confirm that the observed changes affect the translocation/insertion process of OprD in the inner/outer membrane. Aberrant interactions of outer membrane proteins with their cognate chaperones or defects in the Bam translocation complex may indeed have significant effects on the folding and assembly of these proteins. 56 Table 4 summarizes the complexity of resistance mechanisms found in the ICU strains.
